clearance – Page 30 – Communicable Diseases Research

Effects of Short-Term Low-Dose Glucocorticoids for Patients with Mild COVID-19

Clinical Study

Published on 2020-09-232022-10-27
Journal: BioMed Research International [Category] COVID-19,

Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients

스파이크, 막 및 뉴클레오캡시드 SARS-CoV-2 단백질에 대한 강력한 T 세포 반응은 심각한 COVID-19 환자의 회복과 관련이 없습니다

Article

Published on 2020-09-222022-09-11
Journal: Cell Reports Medicine [Category] MERS, SARS, 진단, 치료법,

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

COVID-19로 입원한 환자를 대상으로 한 초기 Favipiravir 요법 대 후기 Favipiravir 요법의 전향적 무작위 공개 표지 시험

Clinical Trial

Published on 2020-09-212022-08-08
Journal: Antimicrobial Agents and Chemotherapy [Category] 임상, 진단, 치료제,

[키워드] 1:1 95% CI 95% confidence interval adjusted hazard ratio adolescents and adult antiviral therapy approved assigned Asymptomatic Avigan clearance clinical clinical trials conducted Cooperative COVID-19 death defervescence Disease progression Eligible patients Endpoint enrolled Exploratory endpoints Favipiravir Fever group hospital Hyperuricemia IMPROVE in viral Influenza Japan late treatment group Multicenter trial occurred Open-label oral broad-spectrum inhibitor Patient performance status primary endpoint Prospective Randomized randomized clinical trial Randomly reduction in regimen Registered registry resolution of symptoms reverse transcription-PCR RNA polymerase RNA-dependent RNA polymerase RT-PCR secondary endpoint significantly the patient therapy time to defervescence transient hyperuricemia Treatment treatment group treatment of influenza Viral viral clearance Viral load Viral RNA viral RNA-dependent RNA polymerase with COVID-19
[DOI] 10.1128/AAC.01897-20 PMC 바로가기 [Article Type] Clinical Trial

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Clinical Trial

Published on 2020-09-212022-10-27
Journal: Antimicrobial Agents and Chemotherapy [Category] COVID-19,

[키워드] 1:1 95% CI 95% confidence interval adjusted hazard ratio adolescents and adult antiviral therapy approved assigned Asymptomatic Avigan clearance clinical conducted Cooperative COVID-19 death Disease progression Endpoint enrolled Favipiravir Fever group hospital IMPROVE in viral Japan late treatment group Multicenter trial occurred Open-label oral broad-spectrum inhibitor Patient performance status primary endpoint Prospective Randomized randomized clinical trial Randomly reduction in regimen Registered registry resolution of symptoms reverse transcription-PCR RNA-dependent RNA polymerase RT-PCR secondary endpoint significantly the patient therapy time to defervescence transient hyperuricemia Treatment treatment group treatment of influenza viral clearance with COVID-19
[DOI] 10.1128/AAC.01897-20 PMC 바로가기 [Article Type] Clinical Trial

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Clinical Trial

Published on 2020-09-212022-10-27
Journal: Antimicrobial Agents and Chemotherapy [Category] Coronavirus, COVID-19, SARS,

[키워드] 1:1 95% CI 95% confidence interval adjusted hazard ratio adolescents and adult antiviral therapy approved assigned Asymptomatic Avigan clearance clinical conducted Cooperative COVID-19 death Disease progression Endpoint enrolled Favipiravir Fever group hospital IMPROVE in viral Japan late treatment group Multicenter trial occurred Open-label oral broad-spectrum inhibitor Patient performance status primary endpoint Prospective Randomized randomized clinical trial Randomly reduction in regimen Registered registry resolution of symptoms reverse transcription-PCR RNA-dependent RNA polymerase RT-PCR secondary endpoint significantly the patient therapy time to defervescence transient hyperuricemia Treatment treatment group treatment of influenza viral clearance with COVID-19
[DOI] 10.1128/AAC.01897-20 PMC 바로가기 [Article Type] Clinical Trial

Regulation of Angiotensin- Converting Enzyme 2 in Obesity: Implications for COVID-19

Physiology

Published on 2020-09-182022-10-31
Journal: Frontiers in Physiology [Category] COVID-19,

[키워드] ACE2 ACE2 expression adipose aggravate angiotensin angiotensin-converting enzyme 2 cardiovascular disease caused cells changes in chronic disease clearance correlated COVID-19 COVID-19 pandemic dataset described diabete dysregulated expression expression of gene Host host cell in silico in vitro in vitro result increased risk infected with SARS-CoV-2 Inflammation Injury involved knowledge lipid metabolism lung lung epithelial cell Lungs mechanism Mortality novel coronavirus SARS-CoV-2 obese obese patient obesity pathway Patient Protein pulmonary inflammation receptor regulated Regulation risk factor SARS-CoV-2 severe complication shown Signaling significant increase smoking subject subjects suppression tissue TMPRSS2 transcriptomic data upregulation validation viral entry viral replication virus
[DOI] 10.3389/fphys.2020.555039 PMC 바로가기 [Article Type] Physiology

Clozapine prescribing in COVID-19 positive medical inpatients: a case series

Case Series

Published on 2020-09-132022-10-28
Journal: Therapeutic Advances in Psychopharmacology [Category] COVID-19,

Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-09-092022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Ability Ability to walk Activation adhere administer ambulatory patient anatomical Anticoagulant treatment anticoagulation antiplatelet Atrial fibrillation baseline bleeding Blinding block size body temperature calculated Cardiovascular events characterized Chemotherapy clearance clinical benefit clinically Coagulation Coagulopathy Comorbidity Comparator group conducted contraindication control group coronary syndrome coronavirus cough COVID-19 creatinine criteria Critical current death defined diagnosed diagnosed with COVID-19 Diagnosis Disseminated intravascular coagulation dissemination dose Efficacy elderly element eligibility criteria eligible enoxaparin enrolment event event rate experimental group Face mask FIVE fixed heart failure help heparin-induced thrombocytopenia Hospitalization hospitals hygiene hypersensitivity impairment IMPROVE In-hospital Inflammation information injection inoperable Intervention intervention group invasive Ischemia Laboratory lack Last Liver disease lower limb major bleeding malignancy multicentre Myocardial number objective Older Open-label outcome parameter participant Participation Patient performed Platelet Positive test Presence prevention protocol provided Radiotherapy randomised randomised controlled trial randomization randomization ratio Randomized Randomized controlled trial receive reduce renal respiratory symptom resulting risk factor Sample size SARS-CoV2 secondary Seven Shortness of breath sore throat Spinal cord injury status Stratified randomization stroke Study protocol Support surgical survival symptomatic the patient therapy Thromboprophylaxis thrombosis total sample size Transport trauma Travel treated Treatment undergo university university hospital Venous Thromboembolism vessel viral disease VTE website
[DOI] 10.1186/s13063-020-04678-4 PMC 바로가기 [Article Type] Letter

The Possibility and Cause of Relapse After Previously Recovering From COVID-19: A Systematic Review

Internal Medicine

Published on 2020-09-052022-10-31
Journal: Cureus [Category] COVID-19,

Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2

Report

Published on 2020-09-042022-10-28
Journal: Science (New York, N.y.) [Category] COVID-19, Fulltext, SARS,

[키워드] acute respiratory syndrome Analysis association bind binding pocket block C terminus Cell cells clearance complex complexes coronavirus coronavirus disease COVID-19 disease-causing drug drug design facilitate Host host cells host gene expression host protein human cell immune evasion immune response in vitro Infection inhibit inhibitory innate immune response mechanism Messenger RNA Microscopy mRNA nonstructural protein 1 pandemic Protein resulting ribosomal subunit SARS-CoV SARS-CoV-2 SARS-CoV-2 protein Science suppresse Thom translation translational treat Viral proteins virulence virus
[DOI] 10.1126/science.abc8665 PMC 바로가기 [Article Type] Report